Tags

Type your tag names separated by a space and hit enter

Cannabidiol: Recent advances and new insights for neuropsychiatric disorders treatment.
Life Sci. 2019 May 01; 224:120-127.LS

Abstract

The pharmacological research on the Cannabis sativa-derived compounds has never terminated. Among the phytocannabinoids without psychotropic effects, the prevalent one in Cannabis is cannabidiol (CBD). Although CBD was initially considered a type 2 cannabinoid receptor (CB2R) antagonist, it did not show a good cannabinoidergic activity. Furthermore, heterogeneous results were obtained in experimental animal models of anxiety disorders, psychotic stages and neurodegenerative diseases. Recently, CBD has been authorized by the FDA to treat some rare forms of epilepsy and many trials have begun for the treatment of autism spectrum disorders. This review aims to clarify the pharmacological activity of CBD and its multiple therapeutic applications. Furthermore, critical and conflicting results of the research on CBD are discussed with a focus on promising future prospects.

Authors+Show Affiliations

Department of Molecular and Translational Medicine, Division of Pharmacology, University of Brescia, Brescia, Italy.Department of Molecular and Translational Medicine, Division of Pharmacology, University of Brescia, Brescia, Italy.Department of Molecular and Translational Medicine, Division of Pharmacology, University of Brescia, Brescia, Italy.Department of Molecular and Translational Medicine, Division of Pharmacology, University of Brescia, Brescia, Italy.Department of Molecular and Translational Medicine, Division of Pharmacology, University of Brescia, Brescia, Italy.Department of Molecular and Translational Medicine, Division of Pharmacology, University of Brescia, Brescia, Italy.Department of Neurobiology, Care Sciences and Society, Division of Neurogeriatrics, Karolinska Institutet, Huddinge, Sweden.Department of Molecular and Translational Medicine, Division of Pharmacology, University of Brescia, Brescia, Italy.Department of Molecular and Translational Medicine, Division of Pharmacology, University of Brescia, Brescia, Italy. Electronic address: andrea.mastinu@unibs.it.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

30910646

Citation

Premoli, Marika, et al. "Cannabidiol: Recent Advances and New Insights for Neuropsychiatric Disorders Treatment." Life Sciences, vol. 224, 2019, pp. 120-127.
Premoli M, Aria F, Bonini SA, et al. Cannabidiol: Recent advances and new insights for neuropsychiatric disorders treatment. Life Sci. 2019;224:120-127.
Premoli, M., Aria, F., Bonini, S. A., Maccarinelli, G., Gianoncelli, A., Pina, S. D., Tambaro, S., Memo, M., & Mastinu, A. (2019). Cannabidiol: Recent advances and new insights for neuropsychiatric disorders treatment. Life Sciences, 224, 120-127. https://doi.org/10.1016/j.lfs.2019.03.053
Premoli M, et al. Cannabidiol: Recent Advances and New Insights for Neuropsychiatric Disorders Treatment. Life Sci. 2019 May 1;224:120-127. PubMed PMID: 30910646.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cannabidiol: Recent advances and new insights for neuropsychiatric disorders treatment. AU - Premoli,Marika, AU - Aria,Francesca, AU - Bonini,Sara Anna, AU - Maccarinelli,Giuseppina, AU - Gianoncelli,Alessandra, AU - Pina,Silvia Della, AU - Tambaro,Simone, AU - Memo,Maurizio, AU - Mastinu,Andrea, Y1 - 2019/03/22/ PY - 2019/02/13/received PY - 2019/03/21/revised PY - 2019/03/21/accepted PY - 2019/3/27/pubmed PY - 2019/5/21/medline PY - 2019/3/27/entrez KW - Cannabidiol KW - Cannabis sativa KW - Epilepsy KW - Psychiatric disorders SP - 120 EP - 127 JF - Life sciences JO - Life Sci VL - 224 N2 - The pharmacological research on the Cannabis sativa-derived compounds has never terminated. Among the phytocannabinoids without psychotropic effects, the prevalent one in Cannabis is cannabidiol (CBD). Although CBD was initially considered a type 2 cannabinoid receptor (CB2R) antagonist, it did not show a good cannabinoidergic activity. Furthermore, heterogeneous results were obtained in experimental animal models of anxiety disorders, psychotic stages and neurodegenerative diseases. Recently, CBD has been authorized by the FDA to treat some rare forms of epilepsy and many trials have begun for the treatment of autism spectrum disorders. This review aims to clarify the pharmacological activity of CBD and its multiple therapeutic applications. Furthermore, critical and conflicting results of the research on CBD are discussed with a focus on promising future prospects. SN - 1879-0631 UR - https://www.unboundmedicine.com/medline/citation/30910646/Cannabidiol:_Recent_advances_and_new_insights_for_neuropsychiatric_disorders_treatment_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0024-3205(19)30217-6 DB - PRIME DP - Unbound Medicine ER -